Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Shadia Jalal

Showing results (21-30 of 27) with videos related to

Pageof 3
Sort By:
You have reached the last page of results.This site can display upto 27 results.
Cancer Medicine|December 18, 2021
Defining comprehensive biomarker-related testing and treatment practices for advanced non-small-cell lung cancer: Results of a survey of U.S. oncologistsKathryn F Mileham, Caroline Schenkel, Suanna S Bruinooge, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 8, 2018
Abemaciclib in Combination with Single-Agent Options in Patients with Stage IV Non-Small Cell Lung Cancer: A Phase Ib StudyEdward S Kim, Karen Kelly, Luis G Paz-Ares, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 10, 2021
Modernizing Clinical Trial Eligibility Criteria: Recommendations of the ASCO-Friends of Cancer Research Performance Status Work GroupAllison Magnuson, Suanna S Bruinooge, Harpreet Singh, et al.
British Journal of Cancer|September 11, 2020
Phase 1 study of mTORC1/2 inhibitor sapanisertib (TAK-228) in advanced solid tumours, with an expansion phase in renal, endometrial or bladder cancerMartin H Voss, Michael S Gordon, Monica Mita, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 15, 2022
Praluzatamab Ravtansine, a CD166-Targeting Antibody-Drug Conjugate, in Patients with Advanced Solid Tumors: An Open-Label Phase I/II TrialValentina Boni, Mary J Fidler, Hendrik-Tobias Arkenau, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|April 4, 2023
Esophageal and Esophagogastric Junction Cancers, Version 2.2023, NCCN Clinical Practice Guidelines in OncologyJaffer A Ajani, Thomas A D'Amico, David J Bentrem, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|May 9, 2025
Gastric Cancer, Version 2.2025, NCCN Clinical Practice Guidelines In OncologyJaffer A Ajani, Thomas A D'Amico, David J Bentrem, et al.
Pageof 3

Showing results (21-30 of 27) with videos related to

Sort By:
Pageof 3
You have reached the last page of results.This site can display upto 27 results.
Cancer Medicine|December 18, 2021
Defining comprehensive biomarker-related testing and treatment practices for advanced non-small-cell lung cancer: Results of a survey of U.S. oncologistsKathryn F Mileham, Caroline Schenkel, Suanna S Bruinooge, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 8, 2018
Abemaciclib in Combination with Single-Agent Options in Patients with Stage IV Non-Small Cell Lung Cancer: A Phase Ib StudyEdward S Kim, Karen Kelly, Luis G Paz-Ares, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 10, 2021
Modernizing Clinical Trial Eligibility Criteria: Recommendations of the ASCO-Friends of Cancer Research Performance Status Work GroupAllison Magnuson, Suanna S Bruinooge, Harpreet Singh, et al.
British Journal of Cancer|September 11, 2020
Phase 1 study of mTORC1/2 inhibitor sapanisertib (TAK-228) in advanced solid tumours, with an expansion phase in renal, endometrial or bladder cancerMartin H Voss, Michael S Gordon, Monica Mita, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 15, 2022
Praluzatamab Ravtansine, a CD166-Targeting Antibody-Drug Conjugate, in Patients with Advanced Solid Tumors: An Open-Label Phase I/II TrialValentina Boni, Mary J Fidler, Hendrik-Tobias Arkenau, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|April 4, 2023
Esophageal and Esophagogastric Junction Cancers, Version 2.2023, NCCN Clinical Practice Guidelines in OncologyJaffer A Ajani, Thomas A D'Amico, David J Bentrem, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|May 9, 2025
Gastric Cancer, Version 2.2025, NCCN Clinical Practice Guidelines In OncologyJaffer A Ajani, Thomas A D'Amico, David J Bentrem, et al.
Pageof 3